Background: Children with HIV will be on antiretroviral therapy (ART) longer than adults, and therefore the durability of first-line ART and timing of switch to second-line are key questions. We assess the long-term outcome of protease inhibitor and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line ART and viral load switch criteria in children. Methods: In a randomised open-label factorial trial, we compared effectiveness of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a protease inhibitor versus two NRTIs plus an NNRTI and of switch to second-line ART at a viral load of 1000 copies per mL versus 30 000 copies per mL in previously untreated children infected with HIV from Europe and North and South America. Random assignment was by computer-generated sequentially numbered lists stratified by age, region, and by exposure to perinatal ART. Primary outcome was change in viral load between baseline and 4 years. Analysis was by intention to treat, which we defined as all patients that started treatment. This study is registered with ISRCTN, number ISRCTN73318385. Findings: Between Sept 25, 2002, and Sept 7, 2005, 266 children (median age 6·5 years; IQR 2·8-12·9) were randomly assigned treatment regimens: 66 to receive protease inhibitor and switch to second-line at 1000 copies per mL (PI-low), 65 protease inhibitor and switch at 30 000 copies per mL (PI-higher), 68 NNRTI and switch at 1000 copies per mL (NNRTI-low), and 67 NNRTI and switch at 30 000 copies per mL (NNRTI-higher). Median follow-up was 5·0 years (IQR 4·2-6·0) and 188 (71%) children were on first-line ART at trial end. At 4 years, mean reductions in viral load were -3·16 log10 copies per mL for protease inhibitors versus -3·31 log10 copies per mL for NNRTIs (difference -0·15 log10 copies per mL, 95% CI -0·41 to 0·11; p=0·26), and -3·26 log10 copies per mL for switching at the low versus -3·20 log10 copies per mL for switching at the higher threshold (difference 0·06 log10 copies per mL, 95% CI -0·20 to 0·32; p=0·56). Protease inhibitor resistance was uncommon and there was no increase in NRTI resistance in the PI-higher compared with the PI-low group. NNRTI resistance was selected early, and about 10% more children accumulated NRTI mutations in the NNRTI-higher than the NNRTI-low group. Nine children had new CDC stage-C events and 60 had grade 3/4 adverse events; both were balanced across randomised groups. Interpretation: Good long-term outcomes were achieved with all treatments strategies. Delayed switching of protease-inhibitor-based ART might be reasonable where future drug options are limited, because the risk of selecting for NRTI and protease-inhibitor resistance is low. Funding: Paediatric European Network for Treatment of AIDS (PENTA) and Pediatric AIDS Clinical Trials Group (PACTG/IMPAACT). © 2011 Elsevier Ltd.
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: An open-label, randomised phase 2/3 trial
Harrison L.; Babiker A.; Castro H.; Compagnucci A.; Fiscus S.; Giaquinto C.; Gibb D. M.; Harper L.; Hughes M.; McKinney R.; Melvin A.; Mofenson L.; Saidi Y.; Smith M. E.; Tudor-Williams G.; Walker A. S.; Brouwers P.; Costello D. ;Ferguson E.; Hodge J.; Jennings C.; Warshaw M.; Spector S.; Stiehm E.; Toye M.; Yogev R.; Aboulker J. P.; De Rossi A.; Darbyshire J.; Debre M.; Klein N.; Pillay D.; Brody B.; Hill C.; Lepage P.; Modlin J.; Poziak A.; Rein M.; Robb M.; Fleming T.; Vella S.; Kim K. M.; Bologna R.; Mecikovsky D.; Pineda N.; Sen L.; Mangano A.; Marino S. ;Galvez C.; Deluchi G.; Zohrer B.; Zenz W.; Daghofer E.; Pfurtscheller K.; Pabst B.; Gomez M. P.; McNeil P.; Jervis M.; Whyms I.; Kwolfe D.; Scott S.; Mussi-Pinhata M. M.; Issac M. L.; Cervi M. C.; Negrini B. V. M.; Matsubara T. C.; de Souza C. B. S. S.; Gabaldi J. C.; Oliveira R. H.; Sapia M. C.; Abreu T.; Evangelista L.; Pala A.; Fernandes I.; Farias I.; Melo M. F.; Carreira H.; Lira L. M.; della Negra M.; Queiroz W.; Lian Y. C.; Pacola D. P.; Pinto J.; Ferreira F.; Kakehasi F.; Martins L.; Diniz A.; Lobato V.; Diniz M.; Cleto S.; Costa S.; Romeiro J.; Dollfus C.; Tabone M. D.; Courcoux M. F.; Vaudre G.; Dehee A.; Schnuriger A.; Le Gueyades N.; De Bortoli C.; Mechinaud F.; Reliquet V.; Arias J.; Rodallec A.; Andre E.; Falconi I.; Le Pelletier A.; Monpoux F.; Cottalorda J.; Mellul S.; Lachassinne E.; Galimand J.; Rouzioux C.; Chaix M. L.; Benabadji Z.; Pourrat M.; Firtion G.; Rivaux D.; Denon M.; Boudjoudi N.; Nganzali F.; Krivine A.; Meritet J. F.; Delommois G.; Norgeux C.; Guerin C.; Floch C.; Marty L.; Hichou H.; Tournier V.; Faye A.; Le Moal I.; Sellier M.; Dehache L.; Damond F.; Leleu J.; Beniken D.; Alexandre-Castor G.; Neubert J.; Niehues T.; Laws H. J.; Huck K.; Gudowius S.; Loeffler H.; Bellert S.; Ortwin A.; Notheis G.; Wintergerst U.; Hoffman F.; Werthmann A.; Seyboldt S.; Schneider L.; Bucholz B.; Feiterna-Sperling C.; Peiser C.; Nickel R.; Schmitz T.; Piening T.; Muller C.; Warncke G.; Wigger M.; Neubauer R.; Butler K.; Chang A. L.; Belger T.; Menon A.; O'connell M.; Barrett L.; Rochford A.; Goode M.; Hayes E.; McDonagy S.; Walsh A.; Doyle A.; Fanning J.; O'connor M.; Byrne M.; O'sullivan N.; Hyland E.; Giacomet V.; Vigano A.; Colombo I.; Trabattoni D.; Berzi A.; Badolato R. ;Schumacher F. ;Bennato V. ;Brusati M. ;Sorlini A. ;Spinelli E. ;Filisetti M. ;Bertulli C. ;Rampon O.; Zanchetta M.; Mazza A.; Stringari G.; Rossetti G.; Bernardi S.; Martino A. ;Castelli Gattinara G.; Palma P.; Pontrelli G.; Tchidjou H.; Furcas A.; Frillici C.; Mazzei A.; Zoccano A.; Concato C.; Duiculescu D.; Oprea C.; Tardei G.; Abaab F.; Mardarescu M.; Draghicenoiu R.; Otelea D.; Alecsandru L.; Matusa R.; Rugina S.; Ilie M.; Netescu S.; Florea C.; Voicu E.; Poalelungi D.; Belmega C.; Vladau L.; Ramos Amador J. T.; Gonzalez Tome M. I.; Rojo Conejo P.; Fernandez M.; Delgado Garcia R.; Ferrari J. M.; Garcia Lopez M.; Mellado Pena M. J.; Martin Fontelos P.; Jimenez Nacher I.; Munoz Fernandez M. A.; Jimenez J. L.; Garcia Torre A.; Penin M.; Pineiro Perez R.; Garcia Mellado I.; Finn A.; Lajeunesse M.; Hutchison E.; Usher J.; Ball L.; Dunn M.; Sharland M.; Doerholt K.; Storey S.; Donaghy S.; Wells C.; Buckberry K.; Rice P.; McMaster P.; Butler P.; Farmer C.; Shenton J.; Haley H.; Orendi J.; Stroobant J.; Navarante L.; Archer P.; Mazhude C.; Scott D.; O'connell R.; Wong J.; Boddy G.; Shackley F.; Lakshman R.; Hobbs J.; Ball G.; Kudesia G.; Bane J.; Painter D.; Sloper K.; Shah V.; Cheng A.; Aali A.; Ball C.; Hawkins S.; Nayagam D.; Waters A.; Doshi S.; Liebeschuetz S.; Sodiende B.; Shingadia D.; Wong S.; Swan J.; Shah Z.; Collinson A.; Hayes C.; King J.; O'connor K.; Lyall H.; Fidler K.; Walters S.; Foster C.; Hamadache D.; Newbould C.; Monrose C.; Campbell S.; Yeung S.; Cohen J.; Martinez-Allier N.; Melvin D.; Dodge J.; Welch S.; Tatum G.; Gordon A.; Kaye S.; Muir D.; Patel D.; Novelli V.; Gibb D.; Moshal K.; Lambert J.; Flynn J.; Farrelly L.; Clapson M.; Spencer L.; Depala M.; Jacobsen M.; Segal S.; Pollard A.; Yeadon S.; Peng Y.; Dong T.; Jeffries K.; Snelling M.; Smyth A.; Smith J. ;Ward B.; Jungmann E.; Ryan C.; Swaby K.; Buckton A.; Smidt E.; Abrams E. J.; Champion S.; Fernandez A. D.; Calo D.; Garrovillo L.; Swaminathan K.; Alford T.; Frere M.; Navarra J.; Borkowsky W.; Deygoo S.; Hastings T.; Akleh S.; Ilmet T.; Mohan K.; Bowen G.; Emmanuel P. J.; Lujan-Zimmerman J.; Rodriguez C.; Johnson S.; Marion A.; Graisbery C.; Casey D.; Lewis G.; Guzman-Cottrill J.; Croteau R.; Acevedo-Flores M.; Gonzalez M.; Angeli L.; Fabregas L.; Valentin P.; Weiner L.; Contello K. A.; Holz W.; Butler M.; Nachman S.; Kelly M. A.; Ferraro D. M.; Rana S.; Reed C.; Yeagley E.; Malheiro A.; Roa J.; Neely M.; Kovacs A. ;Homans J.; Rodriguez Lozano Y.; Puga A.; Talero G.; Sellers R.; Lawrence R. ;Weinberg G. A.; Murante B.; Laverty S.; Deveikis A.; Batra J.; Chen T.; Michalik D.; Deville J.; Elkins K.; Marks S.; Jackson Alvarez J.; Palm J.; Fineanganofo I.; Keuth M.; Deveikis L.; Tomosada W.; Van Dyke R.; Alchediak T.; Silio M.; Borne C.; Bradford S.; Eloby-Childress S.; Nguyen K. ;Rathore M. H.; Alvarez A.; Mirza A. ;Mahmoudi S.; Burke M.; Febo I. L.; Lugo L.; Santos R.; Church J. A.; Dunaway T.; Rodier C.; Flynn P.; Patel N.; Discenza S.; Donohoe M.; Luzuriaga K.; Picard D.; Kline M.; Paul M. E.; Shearer W. T.; McMullen-Jackson C.; Chadwick E.; Cagwin E.; Kabat K.; Dieudonne A.; Palumbo P. ;Johnson J. ;Gaur S.; Cerracchio L.; Foca M.; Jurgrau A.; Vasquez Bonilla S.; Silva G.; Gershon A.; Sullivan J.; Bryson Y.; Frenkel L.; Nelson J.; Hadjou G.; Leonardo S.; Riault Y.; Saidi Y.; Buck L.; Darbyshire J. H.; Forcat S.; Horton J.; Johnson D.; Moore S.; Taylor C.; Collins D.; Buskirk S.; Kamara P.; Nesel C.; Johnson M.; Ferreira A.; Tutko J.; Sprenger H.; Britto P.; Powell C.; Dersimonian R.; Handelsman E.; Ananworanich J.; Belfrage E.; Blanche S.; Bohlin A. B.; Burger D.; Castelli-Gattinara G.; Clayden P.; De Groot R.; Grosch-Worner I.; Lallemant M.; Levy J.; Marczynska M.; Mellado Pena M. J.; Nadal D.; Peckham C.; Rosado L.; Rosso R.; Rudin C.; Scherpbier H.; Stevanovic M.; Thorne C.; Tovo P. A.; Valerius N.
2011-01-01
Abstract
Background: Children with HIV will be on antiretroviral therapy (ART) longer than adults, and therefore the durability of first-line ART and timing of switch to second-line are key questions. We assess the long-term outcome of protease inhibitor and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line ART and viral load switch criteria in children. Methods: In a randomised open-label factorial trial, we compared effectiveness of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a protease inhibitor versus two NRTIs plus an NNRTI and of switch to second-line ART at a viral load of 1000 copies per mL versus 30 000 copies per mL in previously untreated children infected with HIV from Europe and North and South America. Random assignment was by computer-generated sequentially numbered lists stratified by age, region, and by exposure to perinatal ART. Primary outcome was change in viral load between baseline and 4 years. Analysis was by intention to treat, which we defined as all patients that started treatment. This study is registered with ISRCTN, number ISRCTN73318385. Findings: Between Sept 25, 2002, and Sept 7, 2005, 266 children (median age 6·5 years; IQR 2·8-12·9) were randomly assigned treatment regimens: 66 to receive protease inhibitor and switch to second-line at 1000 copies per mL (PI-low), 65 protease inhibitor and switch at 30 000 copies per mL (PI-higher), 68 NNRTI and switch at 1000 copies per mL (NNRTI-low), and 67 NNRTI and switch at 30 000 copies per mL (NNRTI-higher). Median follow-up was 5·0 years (IQR 4·2-6·0) and 188 (71%) children were on first-line ART at trial end. At 4 years, mean reductions in viral load were -3·16 log10 copies per mL for protease inhibitors versus -3·31 log10 copies per mL for NNRTIs (difference -0·15 log10 copies per mL, 95% CI -0·41 to 0·11; p=0·26), and -3·26 log10 copies per mL for switching at the low versus -3·20 log10 copies per mL for switching at the higher threshold (difference 0·06 log10 copies per mL, 95% CI -0·20 to 0·32; p=0·56). Protease inhibitor resistance was uncommon and there was no increase in NRTI resistance in the PI-higher compared with the PI-low group. NNRTI resistance was selected early, and about 10% more children accumulated NRTI mutations in the NNRTI-higher than the NNRTI-low group. Nine children had new CDC stage-C events and 60 had grade 3/4 adverse events; both were balanced across randomised groups. Interpretation: Good long-term outcomes were achieved with all treatments strategies. Delayed switching of protease-inhibitor-based ART might be reasonable where future drug options are limited, because the risk of selecting for NRTI and protease-inhibitor resistance is low. Funding: Paediatric European Network for Treatment of AIDS (PENTA) and Pediatric AIDS Clinical Trials Group (PACTG/IMPAACT). © 2011 Elsevier Ltd.
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Sei sicuro che questo prodotto debba essere cancellato?
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione.
